Patient information and treatment history
| ID | Subtype | Sex | Age | Treatment duration | Prior treatment |
|---|---|---|---|---|---|
| 1 | MRCL | M | 68 | 4 weeks | Surgery, radiation, chemo, LV305 |
| 2 | SS | F | 60 | 2 weeks | (Refused chemotherapy) |
| 3 | SS | M | 50 | 4 weeks | Chemo, LV305 |
| 4 | SS | M | 67 | 4 weeks | Surgery, chemo, radiation |
| 5 | MRCL | M | 49 | 4 weeks | Surgery, chemo, radiation, LV305 |
| 6 | SS | F | 38 | 3 weeks | Radiation, surgery, LV305, atezolizumab |
| 7 | SS | M | 54 | 4 weeks | Surgery, radiation, chemo |
| 8 | SS | F | 24 | 4 weeks | Radiation, surgery, chemo |
NOTE: LV305 is an NY-ESO-1 vaccine that patients received as part of a clinical trial. Some patients received monoclonal antibody treatments as part of their chemotherapy, including olaratumab (anti-PDGFRα), or on a clinical trial of MorAb-004 (anti-endosialin).